The stock is listed on the NYSE American

Davis Polk advised the underwriters in connection with an $80 million SEC-registered common stock and pre-funded warrants offering by Perspective Therapeutics, Inc. The common stock is listed on the NYSE American under the symbol “CATX.”

Headquartered in Seattle, Washington, Perspective Therapeutics is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The company has proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The company is also developing complementary imaging diagnostics that incorporate the same targeting peptides, which provide the opportunity to personalize treatment and optimize patient outcomes.

The Davis Polk corporate team included partner Yasin Keshvargar and associates Christian Knoble, Kanger Jin and Yuchen Xie. The tax team included partner Kara L. Mungovan and associate Justin Corvino. The intellectual property team included partner David R. Bauer and associate Gabrielle Mazero. All members of the Davis Polk team are based in the New York office.

Copy link to share post